Beijing’s new rules for state-led bulk tendering of medical drugs are the latest example of its “anti-involution” drive to combat cutthroat competition, a move analysts said would favour more established players.
“The centralised bulk procurement rules optimisation is a sign that the National Healthcare Security Administration is proactively pushing Beijing’s anti-involution agenda within the pharmaceutical sector as part of efforts to bolster domestic consumption,” Guotai Haitong Securities’…
